Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
OpenAI Nears Astra AI Model Launch With Safety Focus 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
France Targets Shein, Temu With Fast-Fashion Fees 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
OpenAI Rejects Apple Trade Secret Theft Claims 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Add as a preferred source on Google
DURHAM, N.C., March 08, 2018 -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Cowen 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 10:40 a.m. ET in Boston, Massachusetts.
A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has been accepted for priority review by FDA for this initial indication with a PDUFA goal date of May 21, 2018.
Contacts
Mark W. Hahn
(919) 338-7936
[email protected]
Westwicke Partners
John Woolford
(443) 213-0506
[email protected]
